Oncolytics Biotech^® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer

Oncolytics Biotech^®, Inc. announced alignment with the US FDA regarding the design of its pivotal study of pelareorep in combination with standard-of-care therapy for the first-line treatment of metastatic pancreatic ductal adenocarcinoma.